ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Citeline Introduces Global Patient Insights

NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Citeline announces the launch of Global Patient Insights, the industry’s most comprehensive view of the worldwide patient landscape, designed to optimize the site selection process for clinical trial sponsors.

Global Patient Insights seamlessly integrates real-world data on patient population and diversity with Sitetrove’s best-in-class site and investigator intelligence. This robust RWD dataset includes global electronic health records, census and epidemiology data, along with U.S. social determinants of health (SDOH) and medical claims data​.

The race to develop a COVID-19 vaccine underscored the importance of diversity in clinical trials. Despite efforts to improve trial diversity by regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, clinical trials still lack representation among key racial and ethnic minority groups.

With Global Patient Insights, study sponsors will be able to easily locate sites with clinically relevant and diverse patient populations by:

  • Prioritizing countries and global sites with higher volumes of clinically relevant patient populations 
  • Identifying U.S. physicians near investigators with access to the right patients for referrals​
  • Visualizing patient populations via dynamic dashboards and heatmaps

“Global Patient Insights takes Sitetrove to an exciting new level,” says Christina Masturzo, Citeline Vice President, Product Management. “For sponsors, it’s the best of both worlds: our gold-standard Sitetrove data, coupled with information-rich real-world data. In fact, our product team refers to it as ‘Sitetrove on steroids.'

"Our goal at Citeline is to get the right treatments to the right patients at the right time. We do this by guiding sponsors throughout the drug development life cycle, from study design and protocol development through to site selection, patient recruitment and, ultimately, enrollment.”

Learn more about Citeline’s Global Patient Insights at Citeline.com.

About Citeline  
Citeline, a Norstella company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.

Citeline’s global teams of analysts, journalists, and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering them with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts, and more. For more information on one of the world’s most trusted health science partners, visit Citeline and follow on LinkedIn and X.

Citeline PR contact: 
Diffusion PR for Citeline
citeline@diffusionpr.com 
(213) 318-4500


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.38
+4.73 (2.02%)
AAPL  260.48
-0.01 (-0.00%)
AMD  245.04
+8.40 (3.55%)
BAC  52.54
-0.17 (-0.32%)
GOOG  315.72
-0.65 (-0.21%)
META  629.86
+1.47 (0.23%)
MSFT  370.87
-2.20 (-0.59%)
NVDA  188.63
+4.72 (2.57%)
ORCL  138.09
+0.23 (0.17%)
TSLA  348.95
+3.33 (0.96%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.